Skip to main content

Hay Fever

5
Pipeline Programs
2
Companies
3
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
3
Early DiscoveryClinical DevelopmentMarket

On Market (3)

Approved therapies currently available

ALVESCOApproved
ciclesonide
Unknown Company
inhalation2008
35M Part D
OMNARISApproved
ciclesonide
Unknown Company
nasal2007
923K Part D
ZETONNAApproved
ciclesonide
Unknown Company
nasal2012
323K Part D

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
2
CiclesonidePhase 31 trial
Ciclesonide nasal sprayPhase 31 trial
Active Trials
NCT00261287Completed102Est. Jun 2006
NCT00305487Completed660Est. Oct 2006
Innovation Pharmaceuticals
1 program
Yoghurt with L. plantarum strainN/A1 trial
Active Trials
NCT01137357Completed60Est. Dec 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaCiclesonide nasal spray
AstraZenecaCiclesonide
Innovation PharmaceuticalsYoghurt with L. plantarum strain

Clinical Trials (3)

Total enrollment: 822 patients across 3 trials

NCT00305487AstraZenecaCiclesonide nasal spray

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Start: Mar 2006Est. completion: Oct 2006660 patients
Phase 3Completed
NCT00261287AstraZenecaCiclesonide

Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

Start: Nov 2005Est. completion: Jun 2006102 patients
Phase 3Completed
NCT01137357Innovation PharmaceuticalsYoghurt with L. plantarum strain

Probiotics for Reduction Of Markers In Subjects With Allergy

Start: Nov 2008Est. completion: Dec 200860 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.